#DVAX makes headlines as pre-market mover and top gainer, following Sanofi's $2.2 billion acquisition.

Today’s most cited tickers with positive sentiment (last 24h):

#NVDA: 21
#SPY: 16
#NKE: 16
#TSLA: 13
#ASTS: 12
#AMZN: 8
#SPX: 7
#SOBR: 6
#GOLD: 6
#SP500: 5
#PATH: 5
#DVAX: 5
#TSM: 4
#SIDU: 4
#MU: 4
#KALA: 4

BREAKING NEWS: ( NASDAQ: #DVAX ) Market Perform Recommendation Issued On DVAX By William Blair

📢 Stocks Trending NOW: #MRNA #INTC #PATH #NKE #DVAX #KLAC #INDP #DRMA #MWG #ADI

Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline Sanofi (acquirer) will acquire Dynavax (Nasdaq: DVAX) for $15.50 per share in cash, representing ~$2.2 billion equity value and a 39% premium to Dynavax's Dec 23, 2025 close. The offer funds the marketed adult hepatitis B vaccine HEPLISAV-B (two-dose regimen) and Dynavax's phase 1/2 shingles candidate Z-1018, plus additional pipeline projects.The transaction is unanimously approved by the Dynavax board, is expected to close in Q1 2026 subject to customary conditions including majority tender, HSR clearance, and foreign regulatory approvals, and will be funded from Sanofi cash resources.

#DVAX Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline

www.stocktitan.net/news/DVAX/sanofi-to-acqu...

Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program Dynavax (NASDAQ: DVAX) reported Q3 2025 results and announced a new $100 million share repurchase program on Nov 5, 2025. HEPLISAV-B quarterly net product revenue was $90.0M, up 13% YoY, with U.S. total market share ~46% and retail share ~63%. Full-year HEPLISAV-B guidance remains $315–$325M. GAAP net income was $26.9M and adjusted EBITDA was $35.5M for Q3. Cash, cash equivalents and marketable securities totaled $647.8M at Sept 30, 2025. Dynavax entered an exclusive license with Vaxart for an oral COVID-19 vaccine (upfront $25M + $5M equity; $50M contingent payment after Phase 2b), and presented positive topline Phase 1/2 shingles data for Z-1018 at IDWeek.

#DVAX #VXRT Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

www.stocktitan.net/news/DVAX/dynavax-report...

Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program Dynavax (Nasdaq: DVAX) entered an exclusive worldwide license for Vaxart's oral COVID-19 vaccine program on Nov 5, 2025, paying a $25M upfront license fee plus a $5M equity investment. Vaxart will fund and run the ongoing Phase 2b trial (≈5,400 participants) through an EOP2 meeting with FDA; topline data are expected in late 2026. After the Phase 2b readout Dynavax may elect to assume development, paying an additional $50M and potential milestones up to $195M (regulatory) and $425M (sales) plus low‑to‑mid‑teens royalties.

#DVAX #VXRT Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

www.stocktitan.net/news/DVAX/dynavax-enters...

Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial Dynavax (Nasdaq: DVAX) presented positive topline Part 1 data from its Phase 1/2 trial of shingles vaccine candidate Z-1018 at IDWeek 2025 and has initiated Part 2.Key points: Z-1018 (multiple gE doses with CpG 1018 ± alum) showed anti-gE IgG and gE-specific CD4+ T-cell vaccine response rates comparable to Shingrix at four weeks after dose 2, plus robust polyfunctional CD4+ responses and a favorable tolerability profile. Dynavax advanced a 100 mcg gE + CpG 1018 + alum, 0/8-week regimen into Part 2, which has dosed first participants and plans ~324 adults aged 70+ with topline data expected in H2 2026.

#DVAX Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial

www.stocktitan.net/news/DVAX/dynavax-presen...

Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile Dynavax Technologies (Nasdaq: DVAX) announced positive topline results from Part 1 of its Phase 1/2 clinical trial for Z-1018, its novel shingles vaccine candidate, demonstrating comparable efficacy to Shingrix with better tolerability. The trial's selected dose achieved a 100% humoral vaccine response rate and 89.7% cellular immune response rate.Z-1018 showed significantly lower adverse reactions compared to Shingrix, with only 12.5% reporting grade 2-3 local reactions versus 52.6% for Shingrix, and 27.5% reporting grade 2-3 systemic reactions versus 63.2% for Shingrix. The company will advance the 100 mcg dose with CpG 1018 and alum adjuvant using an 8-week dosing interval to Part 2 of the trial in adults 70+ years, scheduled for 2H 2025.

#DVAX Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile

www.stocktitan.net/news/DVAX/dynavax-announ...

Dynavax Earnings Surge 31% to Record $92M as HEPLISAV-B Dominates Hepatitis Market Record Q2 revenue hits $92M driven by HEPLISAV-B growth. Key shingles vaccine data due August. See how Dynavax plans to capture 60% market share by 2030.

#DVAX Dynavax Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/DVAX/dynavax-report...

Dynavax Technologies Celebrates the Election of Board Members at 2025 Annual Meeting In a pivotal moment, Dynavax Technologies announces the election of its four board nominees, confirming strong shareholder support and a commitment to strategic growth.

Dynavax Technologies Celebrates the Election of Board Members at 2025 Annual Meeting #United_States #Dynavax_Technologies #Emeryville #HEPLISAV-B #DVAX

Dynavax Secures Total Victory at Annual Meeting: Shareholders Back All Directors and Major Governance Changes Stockholders show full confidence in Dynavax's strategy, electing all four director nominees and approving board declassification. See what this means for governance.

#DVAX Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting

www.stocktitan.net/news/DVAX/dynavax-stockh...

Dynavax's 203% Returns at Stake as Proxy Fight Reaches Final Showdown Against Deep Track Key proxy firms support Dynavax's board nominees against Deep Track's challenge. Company touts 203% five-year returns vs peers' 9%. Critical vote June 11. See analysis.

#DVAX Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting

www.stocktitan.net/news/DVAX/dynavax-urges-...

Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value Dynavax Technologies (DVAX) has filed an investor presentation defending against Deep Track's proxy contest ahead of its 2025 Annual Meeting. The company highlights its 203% total stockholder return over five years, significantly outperforming vaccine peers (9%) and the S&P Biotechnology Index (-17%). HEPLISAV-B® achieved $268 million in net product revenue in 2024 with 44% U.S. market share. Q1 2025 showed strong growth with HEPLISAV-B® revenue up 36% YoY to $65 million. The company generated over $950 million in revenue during 2020-2022 through pandemic-related business development. Dynavax has completed 85% of its $200 million share repurchase program authorized in November 2024. The company opposes Deep Track's proposal to monetize HEPLISAV-B® and return all cash to shareholders, arguing it would jeopardize long-term growth opportunities.

#DVAX Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value

www.stocktitan.net/news/DVAX/dynavax-files-...

Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum Dynavax Technologies (DVAX) issued a response to Deep Track Capital's investor presentation and mailed a letter to stockholders ahead of its 2025 Annual Meeting. The company reported strong Q1 2025 results with total revenue of $68.2M (34% YoY growth) and HEPLISAV-B® revenue of $65M (36% YoY growth). HEPLISAV-B® achieved ~43% U.S. market share. The company has completed $172M of its $200M share repurchase program. Dynavax announced new pipeline programs including Pandemic Influenza (Phase 1/2 in Q2 2025) and Lyme Disease (clinical development in 2027). The company urges stockholders to vote "FOR" its four director nominees on the GOLD proxy card, opposing Deep Track's proposal which they argue would harm long-term value. Dynavax has delivered 203% returns over five years, outperforming vaccine peers (9%) and the S&P Biotech Index (-17%).

#DVAX Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum

www.stocktitan.net/news/DVAX/dynavax-issues...

Dynavax Reports Record Q1 Earnings: HEPLISAV-B Sales Jump 36% as Company Unveils New Vaccine Programs Q1 revenue hits $65M driven by HEPLISAV-B growth. See details on new shingles, influenza and Lyme disease vaccine programs advancing to clinical trials. Get insights.

#DVAX Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs

www.stocktitan.net/news/DVAX/dynavax-report...

Deep Track Capital Challenges Dynavax Board: 14.5% Stakeholder Demands Strategic Overhaul Deep Track releases investor presentation pushing for board changes at Dynavax. Key focus: capital allocation and value creation strategy. See full activist agenda.

#DVAX Deep Track Capital Releases Investor Presentation on Dynavax Technologies

www.stocktitan.net/news/DVAX/deep-track-cap...

14% Shareholder Battles Dynavax Board: Settlement Rejected, Proxy Fight Looms Deep Track Capital criticizes board entrenchment as Dynavax rejects settlement offer. Major shareholder prepares for 2025 proxy battle. See full governance implications.

#DVAX Deep Track Capital Comments on Dynavax Technologies’ Rejection of Most Recent Settlement Offer

www.stocktitan.net/news/DVAX/deep-track-cap...

Dynavax Fights $950M Revenue Giant's Board Control: 300% Returns at Stake Record HEPLISAV-B sales hit $268M with 44% market share as Dynavax defends growth strategy against activist investor seeking board control. See full analysis.

#DVAX Dynavax Files Preliminary Proxy Statement

www.stocktitan.net/news/DVAX/dynavax-files-...

Can Dynavax's New $225M Debt Deal Transform Its Financial Future? Strategic refinancing cuts interest rates, extends debt maturity to 2030, and includes $8M share repurchase, strengthening Dynavax's capital structure

#DVAX Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase

www.stocktitan.net/news/DVAX/dynavax-announ...

Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance Dynavax Technologies (DVAX) reported strong financial results for Q4 and full year 2024, with HEPLISAV-B net product revenue growing 26% year-over-year to $268.4 million. The company's Q4 revenue reached $71.1 million, up 39% from the previous year.Key highlights include:HEPLISAV-B U.S. market share increased to 44% by end of 2024Full year 2024 GAAP net income of $27.3 million ($0.21 per share)Cash position of $713.8 million as of December 31, 2024Adjusted EBITDA of $51.9 million for 2024, up 329% year-over-yearFor 2025, Dynavax expects HEPLISAV-B net product revenue between $305-325 million and adjusted EBITDA of at least $75 million. The company plans to complete its $200 million share repurchase program and anticipates top-line results from its Phase 1/2 shingles vaccine trial in Q3 2025.

#DVAX Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance

www.stocktitan.net/news/DVAX/dynavax-report...

Record Revenue vs Board Control: Inside Dynavax's $714M Battle with Deep Track Capital Dynavax achieves 26% revenue growth, secures $30M DoD contract, and implements $200M buyback while defending board against activist investor challenge.

#DVAX Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy

www.stocktitan.net/news/DVAX/dynavax-respon...

Dynavax's HEPLISAV-B Hits Record $268M Revenue, Secures Major DoD Vaccine Contract Dynavax reports 26% YoY growth for HEPLISAV-B, targeting 60% of $900M hepatitis B market by 2030. Adds $30M DoD plague vaccine contract amid strong cash position.

#DVAX Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Highlights

www.stocktitan.net/news/DVAX/dynavax-announ...

#DVAX Dynavax to Present at the 7th Annual Evercore HealthCONx Conference

www.stocktitan.net/news/DVAX/dynavax-to-pre...